[8-K] SELLAS Life Sciences Group, Inc. Reports Material Event
SELLAS Life Sciences Group disclosed that it has issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated by reference, but the company states the press release is furnished and not deemed "filed" for purposes of certain securities laws.
The Form identifies the registrant and trading symbol SLS on Nasdaq, provides principal office contact details, and is signed by John T. Burns, Senior Vice President and Chief Financial Officer. The 8-K itself does not present the underlying financial figures; readers must consult Exhibit 99.1 for complete results and the corporate update.
SELLAS Life Sciences Group ha comunicato di aver diffuso un comunicato stampa con i risultati finanziari per il trimestre terminato il 30 giugno 2025 e un aggiornamento societario. Il comunicato 猫 fornito come Allegato 99.1 al presente Modulo 8-K ed 猫 incorporato per riferimento, ma la societ脿 precisa che il comunicato 猫 fornito e non 猫 considerato 'depositato' ai fini di alcune leggi sui titoli.
Il Modulo indica il registrante e il simbolo di negoziazione SLS su Nasdaq, fornisce i contatti della sede principale ed 猫 firmato da John T. Burns, Senior Vice President e Chief Financial Officer. L'8-K non riporta i dati finanziari sottostanti; i lettori devono consultare l'Allegato 99.1 per risultati completi e l'aggiornamento aziendale.
SELLAS Life Sciences Group divulg贸 que emiti贸 un comunicado de prensa anunciando sus resultados financieros del trimestre cerrado el 30 de junio de 2025 y proporcionando una actualizaci贸n corporativa. El comunicado se adjunta como Anexo 99.1 a este Formulario 8-K y se incorpora por referencia, pero la compa帽铆a aclara que el comunicado se proporciona y no se considera 'presentado' a efectos de determinadas leyes de valores.
El formulario identifica al registrante y el s铆mbolo de cotizaci贸n SLS en Nasdaq, facilita los datos de contacto de la oficina principal y est谩 firmado por John T. Burns, Senior Vice President y Chief Financial Officer. El 8-K en s铆 no presenta las cifras financieras subyacentes; los lectores deben consultar el Anexo 99.1 para obtener los resultados completos y la actualizaci贸n corporativa.
SELLAS Life Sciences Group電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 攵勱赴 鞁れ爜瓿� 須岇偓 鞐呺嵃鞚错姼毳� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堧嫟瓿� 氚濏様鞀惦媹雼�. 頃措嫻 氤措弰鞛愲電� 鞚� Form 8-K鞚� Exhibit 99.1搿� 鞝滌稖霅橃柎 彀胳“毳� 鞙勴暣 韱淀暕霅橃棃鞙茧倶, 須岇偓電� 氤措弰鞛愲臧� 鞝滌稖霅橃柎 'filed'搿� 臧勳＜霅橃 鞎婋姅雼り碃 氇呾嫓頄堨姷雼堧嫟.
頃措嫻 Form鞚� 霌彪鞛愳檧 雮橃姢雼レ潣 瓯半灅 鞁臣 SLS毳� 旮办灛頃橁碃 氤胳偓 鞐半澖觳� 鞝曤炒毳� 鞝滉车頃橂┌, John T. Burns 靾橃劃 攵�靷灔 瓴� 斓滉碃鞛毂呾瀯鞛愱皜 靹滊獏頄堨姷雼堧嫟. 8-K 鞛愳泊鞐愲姅 旮办磮 鞛 靾橃箻臧� 韽暔霅橃柎 鞛堨 鞎婌溂氙�搿� 鞝勳泊 鞁れ爜瓿� 須岇偓 鞐呺嵃鞚错姼電� Exhibit 99.1鞚� 彀胳“頃挫暭 頃╇媹雼�.
SELLAS Life Sciences Group a indiqu茅 avoir publi茅 un communiqu茅 de presse annon莽ant ses r茅sultats financiers pour le trimestre clos le 30 juin 2025 et fournissant une mise 脿 jour d'entreprise. Le communiqu茅 est fourni en tant que Exhibit 99.1 脿 ce formulaire 8-K et est incorpor茅 par r茅f茅rence, mais la soci茅t茅 pr茅cise qu'il est fourni et n鈥檈st pas consid茅r茅 comme 芦 d茅pos茅 禄 au regard de certaines lois sur les valeurs mobili猫res.
Le formulaire identifie l'enregistrant et le symbole de cotation SLS sur le Nasdaq, fournit les coordonn茅es du si猫ge et est sign茅 par John T. Burns, Senior Vice President et Chief Financial Officer. Le 8鈥慘 lui鈥憁锚me ne pr茅sente pas les chiffres financiers sous鈥慾acents ; pour les r茅sultats complets et la mise 脿 jour d'entreprise, il convient de consulter l'Exhibit 99.1.
SELLAS Life Sciences Group gab bekannt, dass es eine Pressemitteilung ver枚ffentlicht hat, in der die Finanzergebnisse f眉r das zum 30. Juni 2025 endende Quartal sowie ein Unternehmensupdate bekanntgegeben werden. Die Pressemitteilung ist als Exhibit 99.1 zu diesem Form 8-K beigef眉gt und durch Verweis eingearbeitet, wobei das Unternehmen erkl盲rt, die Mitteilung werde zwar 眉bermittelt, jedoch im Sinne bestimmter Wertpapiergesetze nicht als 'filed' angesehen.
Das Formular nennt den Eintragspflichtigen und das B枚rsensymbol SLS an der Nasdaq, enth盲lt Kontaktdaten der Hauptniederlassung und ist unterschrieben von John T. Burns, Senior Vice President und Chief Financial Officer. Das 8-K selbst enth盲lt nicht die zugrundeliegenden Finanzzahlen; f眉r vollst盲ndige Ergebnisse und das Unternehmensupdate ist Exhibit 99.1 heranzuziehen.
- Press release furnished as Exhibit 99.1 provides investors with the announced quarterly results and a corporate update
- Disclosure identifies the company and trading symbol (SLS), maintaining regulatory transparency
- The Form 8-K does not include the actual financial figures or detailed metrics; readers must consult Exhibit 99.1
- Information is explicitly "furnished" and not "filed", which limits certain statutory liabilities and may affect legal recourse based on the filing alone
Insights
TL;DR: Routine disclosure; press release furnished but no financials in the 8-K reduces immediate market impact.
The filing notifies investors that quarterly results and a corporate update were released via a press release attached as Exhibit 99.1. Because the Form merely furnishes the press release and explicitly states the content is "not filed," there is limited incremental legal exposure and no additional financial detail included in the 8-K itself. Investors and analysts must review Exhibit 99.1 to assess revenue, earnings, cash position, or any operational changes before drawing conclusions.
TL;DR: Disclosure process follows standard practice; "furnished" designation limits Section 18 liabilities.
The company followed a common compliance route by furnishing a press release as an exhibit rather than filing it, which satisfies public disclosure while limiting certain statutory liabilities. The Form includes the required exhibit list and an authorized officer signature. From a governance standpoint, the filing is procedural and does not, by itself, change board composition, executive roles, or corporate governance policies.
SELLAS Life Sciences Group ha comunicato di aver diffuso un comunicato stampa con i risultati finanziari per il trimestre terminato il 30 giugno 2025 e un aggiornamento societario. Il comunicato 猫 fornito come Allegato 99.1 al presente Modulo 8-K ed 猫 incorporato per riferimento, ma la societ脿 precisa che il comunicato 猫 fornito e non 猫 considerato 'depositato' ai fini di alcune leggi sui titoli.
Il Modulo indica il registrante e il simbolo di negoziazione SLS su Nasdaq, fornisce i contatti della sede principale ed 猫 firmato da John T. Burns, Senior Vice President e Chief Financial Officer. L'8-K non riporta i dati finanziari sottostanti; i lettori devono consultare l'Allegato 99.1 per risultati completi e l'aggiornamento aziendale.
SELLAS Life Sciences Group divulg贸 que emiti贸 un comunicado de prensa anunciando sus resultados financieros del trimestre cerrado el 30 de junio de 2025 y proporcionando una actualizaci贸n corporativa. El comunicado se adjunta como Anexo 99.1 a este Formulario 8-K y se incorpora por referencia, pero la compa帽铆a aclara que el comunicado se proporciona y no se considera 'presentado' a efectos de determinadas leyes de valores.
El formulario identifica al registrante y el s铆mbolo de cotizaci贸n SLS en Nasdaq, facilita los datos de contacto de la oficina principal y est谩 firmado por John T. Burns, Senior Vice President y Chief Financial Officer. El 8-K en s铆 no presenta las cifras financieras subyacentes; los lectores deben consultar el Anexo 99.1 para obtener los resultados completos y la actualizaci贸n corporativa.
SELLAS Life Sciences Group電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 攵勱赴 鞁れ爜瓿� 須岇偓 鞐呺嵃鞚错姼毳� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堧嫟瓿� 氚濏様鞀惦媹雼�. 頃措嫻 氤措弰鞛愲電� 鞚� Form 8-K鞚� Exhibit 99.1搿� 鞝滌稖霅橃柎 彀胳“毳� 鞙勴暣 韱淀暕霅橃棃鞙茧倶, 須岇偓電� 氤措弰鞛愲臧� 鞝滌稖霅橃柎 'filed'搿� 臧勳＜霅橃 鞎婋姅雼り碃 氇呾嫓頄堨姷雼堧嫟.
頃措嫻 Form鞚� 霌彪鞛愳檧 雮橃姢雼レ潣 瓯半灅 鞁臣 SLS毳� 旮办灛頃橁碃 氤胳偓 鞐半澖觳� 鞝曤炒毳� 鞝滉车頃橂┌, John T. Burns 靾橃劃 攵�靷灔 瓴� 斓滉碃鞛毂呾瀯鞛愱皜 靹滊獏頄堨姷雼堧嫟. 8-K 鞛愳泊鞐愲姅 旮办磮 鞛 靾橃箻臧� 韽暔霅橃柎 鞛堨 鞎婌溂氙�搿� 鞝勳泊 鞁れ爜瓿� 須岇偓 鞐呺嵃鞚错姼電� Exhibit 99.1鞚� 彀胳“頃挫暭 頃╇媹雼�.
SELLAS Life Sciences Group a indiqu茅 avoir publi茅 un communiqu茅 de presse annon莽ant ses r茅sultats financiers pour le trimestre clos le 30 juin 2025 et fournissant une mise 脿 jour d'entreprise. Le communiqu茅 est fourni en tant que Exhibit 99.1 脿 ce formulaire 8-K et est incorpor茅 par r茅f茅rence, mais la soci茅t茅 pr茅cise qu'il est fourni et n鈥檈st pas consid茅r茅 comme 芦 d茅pos茅 禄 au regard de certaines lois sur les valeurs mobili猫res.
Le formulaire identifie l'enregistrant et le symbole de cotation SLS sur le Nasdaq, fournit les coordonn茅es du si猫ge et est sign茅 par John T. Burns, Senior Vice President et Chief Financial Officer. Le 8鈥慘 lui鈥憁锚me ne pr茅sente pas les chiffres financiers sous鈥慾acents ; pour les r茅sultats complets et la mise 脿 jour d'entreprise, il convient de consulter l'Exhibit 99.1.
SELLAS Life Sciences Group gab bekannt, dass es eine Pressemitteilung ver枚ffentlicht hat, in der die Finanzergebnisse f眉r das zum 30. Juni 2025 endende Quartal sowie ein Unternehmensupdate bekanntgegeben werden. Die Pressemitteilung ist als Exhibit 99.1 zu diesem Form 8-K beigef眉gt und durch Verweis eingearbeitet, wobei das Unternehmen erkl盲rt, die Mitteilung werde zwar 眉bermittelt, jedoch im Sinne bestimmter Wertpapiergesetze nicht als 'filed' angesehen.
Das Formular nennt den Eintragspflichtigen und das B枚rsensymbol SLS an der Nasdaq, enth盲lt Kontaktdaten der Hauptniederlassung und ist unterschrieben von John T. Burns, Senior Vice President und Chief Financial Officer. Das 8-K selbst enth盲lt nicht die zugrundeliegenden Finanzzahlen; f眉r vollst盲ndige Ergebnisse und das Unternehmensupdate ist Exhibit 99.1 heranzuziehen.
FAQ
What did SELLAS (SLS) disclose in this 8-K?
Are the financial results included directly in the Form 8-K?
Is the press release in Exhibit 99.1 considered "filed" with the SEC?
Who signed the Form 8-K for SELLAS?
Where is the company listed and what is the ticker?
